top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Search

Keith Dionne, Ph.D. Appointed CEO of Luxa Biotechnology

Oct 9, 2024
1 min read

Fort Lee, NJ, October 1, 2024 (Business Wire) -- Dr. Keith Dionne has been appointed as the CEO of Luxa Biotechnology, where he will lead the development of a novel RPESC therapy for dry AMD. With 30 years of experience in biotechnology and cell therapy, Dr. Dionne is well-equipped to drive the company's mission forward. His previous leadership roles and extensive expertise in guiding early-stage biotech firms to success position him as the ideal leader for Luxa's vision.

Read full article here.

Recent Posts

GSK to Pay $950M for Pulmonary Hypertension Drug Aimed at Reducing Bleeding Risk

London, February 25, 2026 (Proactive) -- GSK has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, adding a clinical-stage pulmonary hypertension therapy to its pipeline. The com

LIXTE Names Sidney Braun CEO of Liora Technologies

Boca Raton, FL, February 18, 2026 (Globe Newswire) -- LIXTE Biotechnology Holdings, Inc., a clinical-stage oncology company developing small-molecule cancer therapies and radiotherapy technologies,

Korsana Biosciences Raises $175M to Advance Next-Generation Alzheimer’s Antibody

Waltham, MA, February 18, 2026 (Business Wire) -- Korsana Biosciences announced it has emerged from stealth mode with $175 million in total funding to advance novel therapies for neurodegenerative d

Comments

Life Science Headlines

GSK to Pay $950M for Pulmonary Hypertension Drug Aimed at Reducing Bleeding Risk

LIXTE Names Sidney Braun CEO of Liora Technologies

Korsana Biosciences Raises $175M to Advance Next-Generation Alzheimer’s Antibody

Belén Garijo to Lead Sanofi as CEO

Danaher Corporation to Acquire Masimo Corporation for $9.9B

BD closes $18.8B Biosciences & Diagnostic Solutions deal with Waters

Helus Pharma taps longtime CNS pharma leader Michael Cola as CEO

Eikon prices upsized IPO at $18 to raise about $381M

ZOLL names Eric Knudsen CEO in April Leadership Transition

Lilly to buy Orna Therapeutics for up to $2.4B to push in vivo CAR-T Cell Therapies

bottom of page